4D Molecular Therapeutics FDMT Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's total liabilities?
- 4D Molecular Therapeutics (FDMT) reported total liabilities of $61.07M in Q1 2026.
- How has 4D Molecular Therapeutics's total liabilities changed year-over-year?
- 4D Molecular Therapeutics's total liabilities increased by 32.7% year-over-year, from $46.01M to $61.07M.
- What is the long-term trend for 4D Molecular Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's total liabilities has grown at a 13.8% compound annual growth rate (CAGR), from $31.94M to $61.05M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.